# OnCo record calgb-50303 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/calgb-50303/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "calgb-50303", "NCT00118209" ;
  schema:name "Alliance/CALGB 50303"@en ;
  schema:alternateName "CALGB 50303"@en, "Alliance 50303"@en, "DA-EPOCH-R versus R-CHOP"@en ;
  schema:description "An intensive infusion chemotherapy schedule, widely believed to be better for aggressive lymphoma, was compared head to head with the standard and was not better, only harder to tolerate."@en ;
  schema:url <https://onco.cc/trials/calgb-50303/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00118209>, <https://doi.org/10.1200/JCO.18.01994> ;
  onco:status "negative" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "3" ;
  schema:startDate "2005-05" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/ipi-score/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019/> .